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Immobilised cellulose tris(3,5-dichlorophenylcarbamate) modelled as chiral stationary 
phase in reversed phase conditions. 
Rs model for immobilised cellulose tris(3,5-dichlorophenylcarbamate) in chiral RPLC 
Experimental enantioresolution of structurally unrelated drugs and pesticides connected 
to their topological and molecular descriptors. 
Enantioresolution-topological/molecular descriptor model for unrelated compounds 
The pH-dependent molar total charge of the molecule as key variable for 
enantioresolution. 













Parameter related to the chiral carbon connected with enantioresolution 
Protocol for enantioseparation anticipation 
 
ABSTRACT 
To the best of our knowledge, the prediction of the enantioresolution ability of 
polysaccharides-based stationary phases in liquid chromatography for structurally 
unrelated compounds has not been previously reported. In this study, structural 
information of neutral and basic compounds is used to model their enantioresolution 
levels obtained from an immobilised cellulose tris(3,5-dichlorophenylcarbamate) 
stationary phase in reversed phase conditions. Thirty-four structurally unrelated chiral 
drugs and pesticides, from seven families, are studied. Categorical enantioresolution 
levels (RsC, 0 = no baseline enantioresolution and 1 = baseline enantioresolution) are 
established from the experimental enantioresolution values obtained at a fixed 
experimental conditions. From 58 initial structural variables, three topological 
parameters (two of them connected to the chiral carbon), and six molecular descriptors 
(one of them also related with the chiral carbon), are selected after a discriminant partial 
least squares refinement process. The molar total charge of the molecule at the working 
pH is the most important variable. The relationships between RsC and the most 
important structural variables and the drug/pesticide family are evaluated. An explicit 
model is proposed to anticipate the RsC levels, which provides 100% of correct 




Cellulose tris(3,5-dichlorophenylcarbamate) stationary phase 
Reversed phase liquid chromatography 
Enantioseparations 
Enantioresolution modelling 




Chiral molecules play an important role in life and medicinal sciences as well as 
in other fields such as food and environmental chemistry. Consequently, analytical 
techniques capable of differentiating between enantiomers are of great importance. 
Chromatographic and capillary electromigration techniques are the most employed 













Due to its simplicity and accuracy, high-performance liquid chromatography 
(HPLC) with chiral stationary phases (CSPs) is one of the most widely used analytical 
technique for enantiomeric separations. The basis of analytical enantioseparations, in 
the so-called direct approach, is the formation of transient diastereomeric complexes 
between the compound and the chiral selector coated or immobilized onto the stationary 
phase. Different CSPs containing macromolecular selectors (i.e. proteins, 
polysaccharide derivatives, polymers, etc.), macrocyclic selectors (i.e. cyclodextrins, 
macrocyclic antibiotics, etc.) and low-molecular mass selectors (i.e. ligand exchange, 
chiral ion exchange, etc.) have been developed [1]. More than a hundred CSPs are 
offered commercially and about 20–30 CSPs are the most frequently employed [4]. 
In spite of the wide number of analytical applications of CSPs in HPLC, the 
fundamental mechanisms responsible for the observed chiral separations are not fully 
understood. In fact, today, the evaluation of the ability of a chiral column in HPLC for 
the enantioseparation of compounds is an expensive and time-consuming trial-and-error 
strategy. Thus, the prediction of whether a CPS is able to perform a chiral separation or 
not is of great benefit. Relatively few articles in the literature address this important 
issue in chiral HPLC method development. 
Polysaccharide based stationary phases represent by far the most widely used 
CSPs in HPLC due to their broad applicability for a large structural diversity of 
compounds. These CSPs, which can be coated or immobilised onto the stationary 
support, are cellulose- and amylose-based. These linear helical polymers are composed 
of glucose units with β (1→4) (cellulose) or (1→4) (amylose) linkages. The hydroxyl 
groups of the glucose molecules are derivatised with benzoate or phenylcarbamate 













on the aromatic ring, yielding a large variety of derivatives with different selectivities 
and applications [2-5]. Even, differences in enantioseparations between the CPSs 
containing the same chiral selector either coated or covalently immobilised onto the 
surface of silica have been achieved [4]. 
Selector-selectand complexes are thought to be mediated via hydrogen bonds to 
the CO or NH groups of the carbamate moieties, as well as by π- π interactions between 
the phenyl rings, Van der Waals forces and steric factors [3, 5-8]. Recently, halogen 
bonding has been also described to contribute to selector-selectand complexation [9]. 
In chiral HPLC using polysaccharides-based stationary phases, normal, polar or 
reversed mobile phase conditions can be used. The mobile phase composition 
modulates the recognition process. Different chromatographic behaviours are obtained 
depending on the nature and composition of the mobile phase, due to changes produced 
in the intra-molecular hydrogen bonds of the polysaccharide structure. Thus, reversal of 
the elution order enantiomers depending on the composition of the mobile phase can be 
observed [4]. 
In order to elucidate the chiral recognition mechanism of polysaccharide chiral 
selectors, analytical separation techniques in combination with spectroscopic techniques 
such as NMR spectroscopy, Fourier transform and attenuated total reflectance IR 
spectroscopy, vibrational circular dichroism techniques as well as X-ray crystallography 
have been used [1-8]. Molecular modelling has also become a practical tool for 
evaluating the interactions between polysaccharide-based selectors and chiral 
compounds [2, 10]. 
Chemometric and chemoinformatic data mining methods might be helpful to 













quantitative structure–property relationships (QSPRs) are a powerful option. Different 
QSPR studies have been reported for modelling data in enantioselective 
chromatography using polysaccharides-based stationary phases, some of them are 
presented/reviewed in the paper by Del Rio [11]. In these QSPR models, 
enantioresolution-related information (retention or selectivity values) is correlated with 
different molecular properties of compounds through linear free energy relationships 
(LFERs) studies [13-16], linear solvation energy relationships (LSERs) [17], and 3D-
QSPR properties employing comparative molecular field analysis (CoMFA) [18]. 
Multiple linear regression (MLR) [15-17], artificial neural networks [18], and genetic 
algorithm [16, 18] are used as chemometric techniques. 
These studies are usually carried out for structurally related compounds using 
amylose and cellulose-based CSPs -amylose tris(3,5-dimethylphenylcarbamate) [13, 
15], cellulose tris(3,5-dimethylphenylcarbamate) [18] and immobilised amylose tris(5-
chloro-2-methylphenylcarbamate) [16]-, and normal and polar mobile phases. In these 
studies, information about the functional groups responsible for enantioresolution is 
usually obtained. It should be noted that resolution values between enantiomers have 
never been used as response variable, although it is the most practical term that 
describes how well two peaks are resolved. 
In previous papers [19-20], the enantioresolution level (RsC-level) of 
structurally unrelated basic drugs and pesticides, using sulfated β- and γ-cyclodextrins 
as chiral selectors in electrokinetic chromatography (EKC), was modelled as a function 
of structural parameters. For sulfated β-cyclodextrin, few structural descriptors, easy to 













cyclodextrin, few topological parameters, mainly connected to the chiral carbon (so 
called C*-parameters) were used [20]. 
In this work, 58 structural predictor variables of 34 structurally unrelated 
compounds (basic drugs and pesticides), previously assayed in the above-mentioned 
papers, are tested to model a categorical enantioresolution RsC, as response variable. 
The main aim is to define a protocol able to anticipate the enantioresolution (RsC = 1) 
or not (RsC = 0) of new compounds based on this model. The RsC levels are assigned 
from experimental enantioresolution (Rs) values obtained using an immobilised 
cellulose tris(3,5-dichlorophenylcarbamate) CSP and hydro-organic mobile phases. To 
the best of our knowledge, this is the first report that models the enantioresolution of 
structurally unrelated compounds separated using immobilised cellulose tris(3,5-
dichlorophenylcarbamate) CSP and hydro-organic mobile phases. On the other hand, 
the importance of the predictive power (Pp) statistic to assess a discriminant partial least 
squares for one response categorical variable (DPLS1) refinement is discussed. In 
addition, the relationships between RsC and the most important structural variables and 














2. Materials and methods 
2.1. Instrumentation 
An Agilent Technologies 1100 chromatograph (Palo Alto, CA, USA) with a 
binary pump, an UV–visible diode array detector, a column thermostat and an 
autosampler was used. Data acquisition and processing were performed by means of the 
LC/MSD ChemStation software (B.04.02 SP1 [208], ©Agilent Technologies 2001-
2010). 
Prior to injection into the chromatographic system, analytes solutions were 
filtered through disposable 0.22 m polyethersulphone syringe filters (Frisenette, 
Knebel, Denmark). Mobile phase solutions were vacuum-filtered through 0.22 μm 
Nylon membranes (Micron Separations, Westboro, MA, USA) and were degassed in an 
Elmasonic S60 ultrasonic bath (Elma, Singen, Germany) prior to use. A Crison 
MicropH 2000 pHmeter (Crison Instruments, Barcelona, Spain) was employed to adjust 
the pH of the buffer solutions. 
 
2.2. Chemicals and solutions 
All reagents were of analytical grade. Ammonium acetate, sodium dihydrogen 
phosphate monohydrate, sodium hydroxide, acetonitrile and methanol (®Multisolvent, 
HPLC grade) were from Scharlau, S.L. (Barcelona, Spain). Diethylamine was from 
Acros Organics (Geel, Belgium). 10 mM ammonium acetate buffer solution was 
prepared by dissolving the appropriate amount of ammonium acetate in water and 
adjusting the pH to 8.0 with 2.5 M sodium hydroxide. Ultra Clear TWF UV deionised 













Bicalutamide, brompheniramine maleate, carbinoxamine maleate, 
chlorpheniramine maleate, clemastine fumarate, doxylamine succinate, ethopropazine 
hydrochloride, fenfluramine, hydroxyzine hydrochloride, methadone hydrochloride, 
methotrimeprazine maleate, nomifensine maleate, orphenadrine hydrochloride, pindolol, 
terfenadine, trimeprazine hemi(+)-tartrate and verapamil hydrochloride were from 
Sigma (St. Louis, MO, USA). Citalopram hydrobromide was from Tokyo Chemical 
Industry (Tokyo, Japan). Promethazine hydrochloride and salbutamol sulfate were from 
Guinama (Valencia, Spain). Bupivacaine was from Caiman Chemical Co (Ann Arbor, 
MI, USA). Amlodipine was from Alfa Aesar (Karlsruhe, Germany). All the rest of 
drugs tested were kindly donated by several pharmaceutical laboratories: acebutolol 
hydrochloride by Italfarmaco (Madrid, Spain); atenolol by Zeneca Farma (Madrid, 
Spain); fluoxetine hydrochloride by Alter (Madrid, Spain); mepivacaine hydrochloride 
and prilocaine hydrochloride by Laboratorios Inibsa (Barcelona, Spain); metoprolol 
tartrate by Ciba Geigy (Barcelona, Spain); propanocaine by Laboratorio Seid 
(Barcelona, Spain); propranolol hydrochloride by ICI Farma (Madrid, Spain); timolol 
maleate by Merck Sharp & Dohme (Madrid, Spain); and viloxazine hydrochloride by 
Astra Zeneca (Cheshire, UK). All racemic pesticides (benalaxyl, hexaconazole, 
imazalil, myclobutanil, metalaxyl and penconazole) were from Dr. Ehrenstofer 
(Augsburg, Germany). 
Stock standard solutions of compounds used in this study were prepared by 
dissolving 10 mg of the racemic mixture in 10 mL of methanol. Working solutions were 
prepared by dilution of the stock standard solutions using the mobile phase solution. 














2.3. Methodology for the chiral separation of compounds 
The experimental enantioresolution (Rs) values of the compounds listed in Table 
1 were obtained using an immobilised cellulose tris(3,5-dichlorophenylcarbamate) 
column (Chiralart Cellulose-SC; 3 μm, 150 × 4.6 mm i.d.; YMC Separation Technology 
Co., Ltd.; Tokyo, Japan). A ternary mixture consisting of ammonium acetate buffer (10 
mM, pH 8) / acetonitrile / diethylamine (60/40/0.1, v/v/v) was used as mobile phase. 
The mobile phase flow rate was 1.0 mL min−1 and the injection volume was 2 μL. The 
detection was performed in the UV at 220 nm for all compounds, except for 
ethopropazine, methotrimeprazine, promethazine and trimeprazine whose detection was 
performed at 254 nm. The column was thermostatted at 25 °C. 
 
2.4. Software and calculations 
Most of the structural variables used in this study were taken from the online 
ChemSpider chemical structure database [21] and were previously assayed in a study to 
anticipate the experimental enantioresolution of chiral compounds in electrokinetic 
chromatography using two sulfated cyclodextrins as chiral selectors [19, 20]. The first 
seven variables (x1 to x7) correspond to the C
*-parameters. These parameters are 
calculated as the count of atoms/groups bonded to the chiral carbon (C*), for instance 
C*X (C*-heteroatoms) and C*hA (C*-aromatic heterocycles) [20]. Variables x8 to x25 
correspond to molecular descriptors predicted by ACD/Labs and ChemAxon 
calculations: minimal z length (zmin), molecular surface area (MSA), orbital 
electronegativity of the chiral carbon atom (OEC*) and surface tension (ST), among 
others. Variables x26 to x55 correspond to molecular topological parameters predicted by 













descriptor logarithm of octanol–water partition coefficient (logP, from ACD/Labs), 
variable x56, two additional variables (x57 and x58), the apparent logP at a given pH 
(logD) and the molar total charge (), were calculated in this work at pH 8 (the working 
pH), using the following equations [22]: 
log 𝛿𝑖 = log (
𝛽𝑖ℎ
𝑖
1 + 𝛽1ℎ + 𝛽2ℎ
2 + ⋯ + 𝛽𝑖ℎ




log 𝐷 = log 𝑃 + log 𝛿𝑖 (2) 





In these equations, i is the molar fraction of the neutral form of the compound, 
h is the proton concentration (i.e. h = 10-8 M at pH 8.0), i is the protonation cumulative 
constant (for a polyprotic system, n = K1·K2·…·Ki·…·Kn), aj is the value with its sign 
of the net charge of the considered specie (i.e. -1, 0, +1, +2, …) and j the molar 
fraction of the considered specie at the considered pH. The values of the logarithm of 
the protonation constants (logK) used to calculate the molar fractions were taken from 
the literature [23]. 
It should be noted that logD is available from ACD/Labs only at pH 5.5 and 7.4, 
so we preferred to use eqs. 1 and 2 to perform the calculation at the experimental pH (8) 
used to obtain the enantioresolution data. On the other hand,  (eqs. 1 and 3), non-
included in the above-mentioned papers [19, 20], was introduced for the first time in 













Principal component analysis (PCA) and discriminant partial least squares, for 
one response categorical variable (DPLS1) models have been performed using The 
Unscrambler® v.9.2 multivariate analysis software [24]. 
During DPLS1 model refinement (variable selection stage), the predictive 
power, Pp, has been used as the optimization parameter to define the effective 
predictive ability of the model. Pp was calculated using the following equation [25]: 
Pp = 2EVCV – EV (4) 
where EV is the explained variance and EVCV its cross-validated value for the response 
variable. A value of Pp  55% has been considered acceptable for discriminant models 
[19]. 
 
3. Results and discussion 
3.1. Experimental and categorised enantioresolution 
Table 1 shows the experimental enantioresolution data (Rs) obtained using the 
screening procedure depicted in section 2.3 for the compounds studied (Table S1 in 
supplementary data includes the 2D structure of the compounds). Compounds are 
arranged according to their drug/pesticide families. In previous papers dealing with 
enantioresolution modelling in EKC, the modelling of categorised (RsC) instead of 
experimental Rs values were recommended [19, 20]. The use of a categorical RsC 
variable to be modelled and predicted fits the main aim of the present paper, which is 
just to anticipate whether a new compound will be enantioresolved or not in the 
chromatographic conditions assayed. So, the experimental Rs values were converted 













enantioresolution (e.g. Rs ≳ 1.7; No = 1, 5, 6, 7, 8, 9, 23 and 24 in Table 1) were 
assigned to RsC = 1. The rest of compounds were assigned to RsC = 0, with the 
exception of propranolol (No 27; Rs = 1.4), for which an RsC = 0.5 was selected, taking 
into account that it is close to the baseline enantioresolution in these conditions.  
 
3.2. Structural influence (influential compounds) 
The detection and elimination of influential compounds with dissimilar structure 
is of utmost importance prior to developing any kind of model. These compounds could 
disturb the internal structure of latent variables of the further DPLS1 model, so they 
should be eliminated to avoid the alteration of structure-enantioresolution relationships. 
In order to detect possible influential compounds, a PCA analysis was performed (see 
details in supplementary data). For this purpose, the structural information described in 
section 2.4 were organised into a 3458 X-matrix. The options autoscaled data and 
leave-one-out (LOO) cross-validation were chosen. 
Figure 1A shows the PC1-PC2 bi-plot showing the scores (relationships between 
compounds) and loadings (relationships between variables). As can be observed, 
terfenadine and verapamil (No 22 and 33, respectively, in Table 1; whose scores are 
indicated in the plot) have differential scores in the direction of a superimposed axis 
(dashed line). This axis represents a large set of correlated variables related to the 
molecular size (e.g. variables x18, MSA and x23, MM). For instance, the molecular mass 
(MM) of the compounds No 22 and 33 are 471.70 and 454.60 Da, respectively. 
However, the rest of compound have MM values in the 238.33 to 336.43 Da range. The 
molecular surface area (MSA; from Chem Axon) is another example of molecular 













Å^2, respectively, for the rest of compound are in the 374.70 to 579.98 Å^2 range. 
Thus, fixing threshold limits for one or two of these variables could enable to identify 
new influential compounds without the need to perform a new PCA analysis. 
Figure 1B shows the Influence plot (Residual vs. Leverage) for compounds. It 
confirms that terfenadine and verapamil are influential (high leverage), in agreement 
with the results obtained in previous papers [19, 20]. Influential compounds (with 
different structures from the majority) could disturb the structure-RsC relationship and 
should be eliminated. 
 
3.3. Modelling the structure-RsC relationship (DPLS1) and variable selection process 
DPLS1 modelling was selected to relate the structural data (X-matrix) to the RsC 
data (y-vector), as suggested in previous papers [19, 20]. To build the DPLS1 model, 
the influential compounds No 22 and 33 were omitted. As in the PCA analysis, 
autoscaled data and the LOO cross-validation options were used. 
Several criteria were adopted to optimise the model. Ideally, the model should fit 
the following goals: (i) A primary goal is to achieve full discrimination between the 
group of compounds with predicted RsC = 0 and 1, for the calibration outputs (all 
compounds in the model), and if possible, for the cross-validated outputs; (ii) The 
predictive power Pp has to be  55%, (the recommended level [19]); (iii) The optimal 
number of latent variables (ko) has to be close to 1, for instance, ko = 1 or 2 (ko = 1, is 
the ideal value here since there is just one response variable, RsC); (iv) The final model 














The initial DPLS1 model derived provided full discrimination between 
compounds having RsC = 0 and 1 in the calibration set (see Fig. S1 in supplementary 
data). Therefore, this initial model fits the primary goal of this work. However, some 
compounds were misclassified in the cross-validated outputs (mainly No 1 and 23, 
validation plot in Fig. S1). In addition, other negative aspects were also observed. A 
poor predictive power was obtained, Pp = 0, due to an excessive distance between EV 
and EVCV, 78.3% and 30.6%, respectively. This fact also justifies the differences in the 
prediction success rates between the calibration and cross-validated outputs. On the 
other hand, a value of ko = 4 was obtained (far from the ideal one), indicating an 
excessive model complexity. Finally, the scaled regression coefficients indicate that 
practically all the variables were non-significant, with the exception of x4 (C*hA), x57 
(logD) and x58 (α). These three variables will probably remain in the final model, but 
most of the rest would contribute negatively to the poor predictive ability of the current 
model. 
Model refinement (e.g. elimination of noisy variables, that is, those with the 
worst Ub/b ratios) has proven to be convenient in order to improve its performance. 
Also Pp has been proposed to control the progress of refinement instead of other more 
common parameters as EV or EVCV [19 and references therein]. In the present study, the 
process of model refinement was performed in two stages, due to the high number of 
variables. In addition, the Pp value was used as an indicator to control the quality of the 
model. 
In the first refinement stage, the elimination of noisy variables was carried out in 
turn in several steps, deleting up to 4 variables at each step. The process was stopped 













b ± Ub values). In this case, model refinement was stopped for 15 remaining variables. 
Figure 2 shows the evolution of the parameters ko and EV, EVCV and Pp while 
decreasing the number of variables into the model during this refinement stage. As can 
be expected, the values of Pp raise and ko decrease along the process, indicating an 
improvement in the quality of the model.  
On the other hand, as can be seen in Figure 2, the use of EV (related with the 
calibration set) to control the refinement progress is not adequate in this case. The 
model refinement from 35 to 31 remaining variables resulted in a decrease in the EV 
values, due to the change from ko = 4 to ko = 2. This decrease in the EV values suggests 
an apparent loss of predictive ability that would lead to incorrectly stopping the 
refinement process. EVCV seems to be a better diagnostic indicator. However, from 31 to 
24 remaining variables (with ko = 2), there is a stabilization of the parameter (even a 
little decrease) that would incorrectly suggest no further improvement, as in the case of 
EV. Therefore, Pp (relating both calibration and cross-validated outputs) is the best 
option to measure the improvement of the DPLS1 model. Pp also exhibits a higher 
relative slope (improvement) than EVCV. To the best of our knowledge, this is the first 
time that the superiority of Pp to control model refinement, compared with other more 
conventional criteria, is outlined. In fact, a high Pp value guaranties a short distance 
between calibration and cross-validated predictions (i.e. the model robustness) and, as a 
consequence, can assure the achievement of the primary goal mentioned above. 
In the second refinement stage, the elimination of variables was performed one 
by one, eliminating each time that one whose elimination greatly improved Pp, without 
affecting negatively the others consolidated rules. This stage was stopped when the 













feature). Some technical details of the final model can be seen in supplementary data 
(Fig S2). Only nine variables, with acceptable b ± Ub values, remained in the final 
model: two chiral-topological parameters, x1 and x4 (C*X and C*hA, respectively), a 
molecular topological parameter, x36 (Arc) and six molecular descriptors, x11, x18 x21, 
x25, x57 and x58 (zmin, MSA, OEC*, ST, logD and , respectively). 
The model exhibited good discrimination between predicted RsC = 0 and 1 data 
for calibration, and cross-validated outputs. It exhibited, a Pp value of 56% (EV = 
78.4% and EVCV = 67.4%), with ko = 2, near to the ideal value. So, the model was 
considered satisfactory for the purpose of this work. The values of the variables 
included in the final model for the compounds studied are shown in Table 2. 
 
3.4. RsC-variables relationships 
The magnitude of the scaled regression coefficients (b-magnitude) reflects the 
importance of each selected variable to describe the enantioresolution. Positive b-values 
indicate positive contributions (i.e. a high value of the variable favours the 
enantioresolution) and vice versa. According to this, α (negative contribution) is the 
variable that contributes the most to enantioresolution since its coefficient doubles the 
importance over the other variables (see Fig S2 in supplementary data). Therefore, 
neutral and low charged compounds (α close to zero) have a priori the largest 
probability of enantioresolution. 
The other eight variables of the model have similar importance between them 
(similar coefficient magnitudes). This fact indicates that their contribution to the 
enantioresolution is almost equivalent. The absence of heteroatoms or aromatic 













(C*), as well as the presence of the aromatic rings in the molecule (aromatic ring count 
(Arc); positive contribution), also improve the enantioresolution. In the same way, low 
zmin and MSA values and high OEC*, ST and logD values enhance the 
enantioresolution. It should be noted that logD but not logP was selected to obtain the 
final model. Thus, for ionisable compounds, the effective hydrophobicity, adjusted with 
the mobile phase pH, could contribute to improve the enantioresolution. 
As stated in the introduction section, the results obtained confirm that 
hydrophobic, electronic and steric factors are the main interactions responsible of 
enantiorecognition in polysaccharide-based stationary phases. 
As can be seen in Table 2, seven of the enantioresolved compounds (No = 5, 6, 
7, 8, 9, 23 and 24) have low α values (in the 0 – 0.33 range), while the majority of the 
non-enantioresolved compounds have α > 0.92. This behaviour is in agreement with that 
previously stated. However, for some compounds the contribution of the rest of 
variables becomes more important than the effect of α. For example, although 
nomifensine (No 1) has a relatively high α value (0.88; unfavourable for RsC), it is 
enantioresolved due to the combination of other favourable parameters (e.g. it has the 
lowest MSA value, 374.7 Å2). On the contrary, enantioresolution was not achieved for 
metalaxyl (No 10) despite being a neutral compound (α = 0; favourable for RsC). This 
molecule has, for instance, one C*X (the C*-N bound) and just one aromatic ring (Arc = 
1), among other non-favourable contributions (see Table 2). 
Figure 3 shows the final DPLS1 score plot. Scores are labelled by their ordered 
numbers (No in Table 1; Figure 3A), RsC values (Figure 3B, upper part) and their 
families (Figure 3C, lower part). As can be seen, compounds having RsC = 1 are located 













S2 in supplementary data). These points correspond to the family 2 (fungicides, except 
metalaxyl, No 10) and to two local anaesthetics and one antidepressant (families 4 and 
1, respectively). In the central part of the score plot, several families are mixed, all of 
them with RsC = 0. β-blockers (family 5, RsC = 0) are located in the left upper 
quadrant, except propranolol (No 27), the only compound close to the baseline 
enantioresolution (RsC = 0.5). Thus, the DPLS1 results are discreetly conditioned by the 
families of the compounds studied. 
 
3.5. Explicit model for enantioresolution anticipation 
In order to easily anticipate whether or not a new compound will be 
enantioresolved, a practical explicit model was derived from DPLS1. For this purpose, 
raw (de-scaled) coefficients were calculated from the scaled ones. The following 
equation was obtained (eq. 5): 
eRs = -1.28 - 0.14 C*X - 0.22 C*hA - 0.078 zmin - 0.0022 MSA + 0.25 OEC* + 
0.024 ST + 0.22 Arc + 0.072 logD - 0.57 α    (5) 
where eRs refers to an output related to Rs that should be seen as an indicative value 
since categorical Rs data were used to obtain the model. Figure 4 shows the eRs outputs 
obtained from eq. 5 vs the initial assigned RsC values (Table 1) for the compounds of 
the calibration set. 
To anticipate enantioresolution, eRs outputs have to be transformed into 
anticipated-RsC (aRsC) outputs, comparable to the categorical (RsC) levels previously 
stablished. For this purpose, as Figure 4 shows, it is necessary to apply the following 













enantioresolution, for eRs between 0.4 and 0.5 and (iii) aRsC = 0, poor or no 
enantioresolution, for eRs < 0.4.  
Alternatively, a simpler approach can be applied to establish if a molecule will 
be completely enantioresolved (aRsC = 1) or not (aRsC = 0). In this case, aRsC levels 
(0 or 1) are calculated by directly rounding the eRs values to integer numbers (without 
decimal digits). Table 2 shows the aRsC values obtained by applying this direct rule. 
Such anticipations are identical to those obtained by applying the previous rules, except 
for propranolol (RsC = 0.5) as expected. For this compound, this approach anticipates 
no full enantioresolution (aRsC = 0), which strictly agrees with the experimental result, 
Rs = 1.4. An anticipation success rate of 100% was obtained by comparing aRsC (Table 
2) and RsC assignations from experimental data (Table 1). 
 
3.6. Protocol for a safe aRsC anticipation and additional remarks 
A complete protocol to perform a safe aRsC anticipation for a new compound in 
the current conditions is: 
 Step-1a. Obtain MSA from ChemAxon (this value will be necessary in further 
steps). Optionally, obtain the molecular mass (MM). 
 Step-1b. If MSA is outside the 350 – 600 Å2  range the anticipation is not 
recommended (for more security, anticipation should not be done if MM is outside 
the 200 - 350 Da range). Otherwise, continue to the next steps. 
 Step-2a. Locate the chiral carbon (C*) in the 2D structure of the chiral compound. 
Find the presence or absence of C*-heteroatoms (C*X) and C*-aromatic 













criteria: C*X presence (1); C*X absence (0); C*hA presence (1); C*hA absence (0). 
Count the aromatic rings in the whole molecule (Arc is also provided by 
ChemAxon). 
 Step-2b. Use ChemAxon to calculate the values of the variables zmin, MSA, OEC*, 
ST and pKa. From ACD/LogP estimate logP. 
 Step-2c. Calculate logD and α at pH 8, according to eqs. 1-3. 
 Step-3. Use eq. 5 to estimate eRs. Round this value to an integer number for a rapid 
anticipation of enantioresolution, (aRsC only 0 or 1). Alternatively, use the 
following criteria for a 3-level aRsC: baseline enantioresolution (aRsC = 1) if eRs > 
0.5, poor or non enantioresolution (aRsC = 0) if eRs < 0.4, and almost full 
enantioresolution (aRsC = 0.5) if eRs is in the 0.4 – 0.5 range. 
 
The LOO cross-validation strategy performed on the final DPLS1 model is 
virtually equivalent to the use of an external validation strategy [25]. Note that in this 
approach, the prediction, in turn, of each single compound (acting at that moment as an 
external validation sample), is made with a model very close to the final model (just 
excluding the compound to be predicted). 
On the other hand, to test the anticipative ability of the protocol with compounds 
non included to build the model, four molecules (fenfluramine, amlodipine, bupivacaine 
and bicalutamide), satisfying the step-1b of the protocol, were first anticipated and then 
chromatographed for experimental confirmation. Table 3 shows the values of the 
predictive variables, the anticipated output (aRsC; consistent with Step 3 of the 
protocol) and the corresponding experimental Rs values. In all cases, experimental 













The compounds included in this study are structurally unrelated (drugs and 
pesticides) compounds. Except fungicides (compounds No 5-10), which are neutral, all 
are basic compounds, most of them fully ionised at pH = 8.0. A priori, the anticipation 
protocol should be applicable for compounds of similar nature, in experimental 
conditions similar to those used in this study (section 2.3). 
 
4. Conclusions 
Structural information of structurally unrelated chiral compounds can be 
connected with experimental enantioresolution data in HPLC obtained using 
immobilised cellulose tris(3,5-dichlorophenylcarbamate) column in reversed phase 
conditions. Safe anticipation of the categorised (i.e. favourable/unfavourable) 
enantioresolution is possible. It requires a precise discriminant PLS-based (DPLS1) 
multivariate study; i.e. combining scaled regression coefficients and their uncertainty 
intervals with the predictive power (Pp) values for a consistent model refinement. Such 
study provides double valuable information: (i) the variables more informative and their 
contribution (positive or negative) to the enantioresolution of a compound (descriptive 
function), and (ii) an explicit equation to anticipate its enantioresolution (predictive 
function). 
From 58 initial structural variables, three topological parameters (two of them 
connected to the chiral carbon), and six molecular descriptors (one of them also related 
with the chiral carbon), are selected after a discriminant partial least squares refinement 
process. The topology surrounding the chiral carbon is a relevant aspect on 
enantioresolution. However, in this case, the molar total charge, which depends on the 













enantioresolution of neutral or low charged basic compounds is favoured. On the other 
hand, the model discriminates between two of the families studied, fungicides and β-
blockers. 
A stepwise protocol facilitates the anticipation of the enantioresolution without 
the need of the previous derived models. It includes threshold limits, based on the 
topological parameter aromatic ring count, to detect influential compounds whose 
anticipation becomes risky. Applying the protocol, an anticipation success rate of 100% 
for the compounds studied is obtained, when compared with the experimental results. 
The high Rs-anticipation effectiveness found suggests that the strategy could serve for 
other RPLC or in general HPLC chiral methods. 
Finally, for a given chiral selector, the experimental enantioresolution values 
depend on the chiral stationary phase features (batch, immobilisation chemistry, 
supplier, etc.). This is the main reason why a categorical instead of quantitative Rs 
variable is used in this work. It is expected that the qualitative output (aRsC = 0 or 1) 
proposed could be transferred to other columns, although it should be confirmed with 
experimental results. 
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Fig. 1. Unscrambler® PCA results. (A) PC1-PC2 bi-plot showing the scores 
(relationships between compounds; +) and loadings (relationships between variables; 



































Fig. 2. DPLS1 outputs as a function of the number of remaining variables in the model 
during the first stage of the refinement process. Explained (EV, ) and cross-validated 
(EVCV, +) variance values for the response variable, predictive power (Pp, ) and 





Fig. 3. Final (refined) DPLS1 score plot. Compounds are labelled by their (A) 
numbered order (No), (B) categorical enantioresolution (RsC) and (C) drug/pesticide 

























































Fig. 4. Enantioresolution discriminant ability of eq. 5. Estimates from eq. 5 (eRs 
outputs) vs. RsC values from Table 1. Horizontal lines at 0.4 and 0.5 separate the three 


























Experimental enantioresolution data (Rs). Compounds are identified by their name and numbered order 
(No). Categorical enantioresolution (RsC) levels are assigned according to the experimental observations: 
RsC = 1 if Rs > 1.7; otherwise, RsC = 0 (with the exception of propranolol; RsC = 0.5 since Rs = 1.4). 
Structural influence investigated by principal components analysis (PCA). The 2D molecular structure 
can be seen in Table S1 (Supplementary data). 
Name No Family a Rs RsC 
Structural 
influence b 
Nomifensine 1 1 6.5 1  
Citalopram 2 1 0.9 0  
Fluoxetine 3 1 0 0  
Viloxazine 4 1 0 0  
Benalaxyl 5 2 6.3 1  
Imazalil 6 2 3.7 1  
Penconazole 7 2 3.6 1  
Hexaconazole 8 2 2.7 1  
Myclobutanil 9 2 1.7 1  
Metalaxyl 10 2 0 0  
Trimeprazine 11 3 0.5 0  
Doxylamine 12 3 1.0 0  
Brompheniramine 13 3 0.6 0  
Chlorpheniramine 14 3 0.5 0  
Orphenadrine 15 3 0.3 0  
Carbinoxamine 16 3 0 0  
Clemastine 17 3 0 0  
Ethopropazine 18 3 0 0  
Hydroxyzine 19 3 0 0  
Methotrimeprazine 20 3 0 0  
Promethazine 21 3 0 0  
Terfenadine 22 3 0 0 Influential 
Mepivacaine 23 4 2.2 1  
Propanocaine 24 4 2.2 1  
Prilocaine 25 4 0.7 0  
Pindolol 26 5 0 0  
Propranolol 27 5 1.4 0.5  
Metoprolol 28 5 0.3 0  
Acebutolol 29 5 0 0  
Atenolol 30 5 0 0  
Salbutamol 31 5 0 0  
Timolol 32 5 0 0  
Verapamil 33 6 0.6 0 Influential 
Methadone 34 7 1.0 0  
a Drug/Pesticide families: 1 (antidepressants), 2 (fungicides), 3 (antihistamines), 4 (local anaesthetics), 5 (β-blockers), 
6 and 7 (other families of drugs). 















Variables selected in the final discriminant partial least squares (DPLS1) model: heteroatoms linked to 
the chiral carbon (C*X), aromatic heterocycles linked to the chiral carbon (C*hA), minimal z length 
(zmin), molecular surface area (MSA), orbital electronegativity of the chiral carbon atom (OEC*), surface 
tension (ST), aromatic ring count (Arc), apparent logarithm of octanol–water partition coefficient (logD) 
and molar total charge (). Their contribution sign to the enantioresolution is indicated in brackets. 
Anticipated-RsC values (aRsC) after rounding the eRs outputs (eq. 5) to integer values. 
No C*X (-) C*hA (-) zmin (-) MSA (-) OEC* (+) ST (+) Arc (+) logD (+) α (-) aRsC 
1 0 0 7.05 374.70 8.42 46.60 2 1.22 0.88 1 
2 1 1 10.86 499.26 9.10 49.90 2 0.72 0.98 0 
3 1 0 8.89 449.60 8.83 33.00 2 2.28 0.98 0 
4 1 0 7.40 391.60 8.86 36.80 1 0.69 0.61 0 
5 1 0 9.68 520.10 8.97 44.50 2 3.88 0.00 1 
6 1 0 7.71 382.90 8.92 40.80 2 3.56 0.06 1 
7 0 0 7.66 389.70 8.25 42.90 2 3.66 0.00 1 
8 0 0 8.17 432.90 9.00 46.10 2 3.66 0.00 1 
9 0 0 8.56 423.80 8.92 44.70 2 2.82 0.00 1 
10 1 0 9.14 459.43 8.48 40.50 1 2.15 0.00 0 
11 0 0 7.69 469.40 7.82 43.50 2 3.54 0.96 0 
12 1 1 8.79 463.90 9.23 39.30 2 1.60 0.88 0 
13 0 1 9.32 432.60 8.58 43.10 2 2.08 0.97 0 
14 0 1 9.29 428.51 8.58 42.10 2 1.91 0.97 0 
15 1 0 8.73 467.00 8.99 38.00 2 3.20 0.88 0 
16 1 1 9.53 444.30 9.15 43.00 2 1.84 0.88 0 
17 1 0 9.62 549.20 9.06 39.70 2 4.13 0.97 0 
18 1 0 8.29 500.40 8.17 42.90 2 4.23 0.98 0 
19 1 0 7.78 579.98 8.54 47.80 2 1.81 0.40 0 
20 0 0 9.86 518.60 7.82 42.80 2 3.50 0.96 0 
21 1 0 8.61 439.30 8.16 44.10 2 3.69 0.92 0 
23 1 0 6.44 423.60 8.76 44.00 1 1.86 0.33 1 
24 1 0 7.76 522.70 8.86 41.10 2 5.30 0.25 1 
25 1 0 8.42 387.30 8.72 38.50 1 1.49 0.44 0 
26 0 0 6.92 399.50 8.83 47.50 2 -0.57 1.86 0 
27 0 0 8.31 426.90 8.83 42.70 2 1.63 0.97 0 
28 0 0 6.50 474.70 8.83 37.10 1 0.11 0.98 0 
29 0 0 6.86 560.30 8.83 43.20 1 0.37 0.97 0 













31 0 0 6.38 405.96 8.84 49.20 1 -1.41 0.96 0 
32 0 0 7.75 497.99 8.83 52.50 1 -1.09 0.98 0 




Application of the protocol to obtain anticipated enantioresolution values (aRsC) for new compounds non 
included to build the model and experimental enantioresolution values (Rs). See further details for other 




















eRs b aRsC Rs 
Fenfluramine 1 0 8.79 359.91 8.05 26.30 1 0.83 0.99 < 0.4 0 0 
Amlodipine 0 0 11.71 570.90 8.42 44.40 1 2.71 0.96 < 0.4 0 0.6 
Bupivacaine 1 0 8.21 517.09 8.82 41.60 1 3.30 0.50 < 0.4 0 0.8 
Bicalutamide 1 0 6.99 527.46 9.44 58.20 2 4.94 0 > 0.5 1 1.7 
a Step-1b criterion. MSA values are in the 350 – 600 Å2 range (anticipation can be performed). 
b Step-3 criterion. eRs outputs from eq. 5 used for anticipating aRsC: baseline enantioresolution (aRsC = 1) if eRs > 
0.5 and poor or non enantioresolution (aRsC = 0) if eRs < 0.4. 
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